Search for European Projects

22 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Systems Biology of Alcohol Addiction: Modeling and validating disease state networks in human and animal brains for understanding pathophysiolgy, predicting outcomes and improving therapy (SyBil-AA)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Alcohol addiction ranks among the primary global causes of preventable death and disabilities in human population, but treatment options are very limited. Rational strategies for design and development of novel, evidence based therapies for alcohol addiction are still missing. Within this project, we will utilize a translational approach based on clinical studies and animal experiments to fill thi ...
Read Project

 13

 FINISHED 

Molecular dissection of titin-based mechanisms in charge of cardiomyocyte dysfunction in terminal feart failure (Titin Signals)

Start date: Jul 1, 2016, End date: Jun 30, 2019,

Chronic heart failure is a leading cause of mortality in the industrialized countries. Pathomechanistically, a variety of diverse stress signals on the cardiomyocyte trigger loss of myofibrils and cardiomyocyte death, thereby activating a vicious cycle of cardiac stress and deterioration during terminal heart failure. Despite the enormous clinical relevance, the exact pathomechanisms in charge rem ...
Read Project

 2

 FINISHED 

Multidisciplinary Approaches to Translational Research In Conduct Syndromes (MATRICS)

Start date: Mar 1, 2014, End date: Feb 28, 2019,

Conduct Disorder (CD) is the key paediatric disorder characterized by severe aggression. It is heterogeneous, and our understanding of the neurobiology to subtype aggression is limited. MATRICS is a multidisciplinary consortium of academic partners and SMEs that focuses on the subtyping of aggression both within CD and of the broader cross-disorder trait of aggression. MATRICS will test the hypoth ...
Read Project

 21

 FINISHED 

Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Start date: Nov 1, 2013, End date: Oct 31, 2018,

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental ...
Read Project

 27

 FINISHED 

"Training in neurodegeneration, therapeutics intervention and neurorepair" (TINTIN)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

"Dopamine neurons play a central role in major illnesses, such as anxiety and mood disorders, schizophrenia, autism-spectrum disorders, Parkinson’s disease, epilepsy, and dementia. A multidisciplinary approach must be taken by European researchers to discover the molecular basis of dopamine neurodegeneration and how new technologies will lead to repair and regeneration of neuronal systems in the b ...
Read Project

 8

 FINISHED 

IMAging GEnetics for MENtal Disorders (IMAGEMEND)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

"Mental disorders are leading causes of disability, absence from work and premature retirement in Europe. While magnetic resonance imaging (MRI) facilities are broadly available and a vast research literature exists, few neuroimaging applications have reached clinical practice in psychiatry. A major problem is that mental illnesses are currently diagnosed as discrete entities defined clinically. I ...
Read Project

 15

 FINISHED 

Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes (TACTICS)

Start date: Jan 1, 2012, End date: Jun 30, 2017,

Compulsivity is characterized by a repetitive, irresistible urge to perform a behavior, the experience of loss of voluntary control over this intense urge, the diminished ability to delay or inhibit thoughts or behaviors, and the tendency to perform repetitive acts in a habitual or stereotyped manner. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders t ...
Read Project

 13

 FINISHED 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Start date: Apr 1, 2012, End date: Mar 31, 2017,

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Read Project

 29

 FINISHED 

OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) (OPTiMiSE)

Start date: Feb 1, 2010, End date: Jul 31, 2016,

OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) will focus on two goals: optimising current treatments in Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project wi ...
Read Project

 25

 FINISHED 

Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE)

Start date: Nov 1, 2010, End date: Apr 30, 2016,

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use ...
Read Project

 17

 FINISHED 

Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia (CRESTAR)

Start date: Nov 1, 2011, End date: Oct 31, 2015,

Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden. First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics. The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to b ...
Read Project

 11

 FINISHED 

Paediatric European Risperidone Studies (PERS)

Start date: May 1, 2010, End date: Apr 30, 2015,

"Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in ado ...
Read Project

 22

 FINISHED 

Suicidality: Treatment Occurring in Paediatrics (STOP)

Start date: Nov 1, 2010, End date: Apr 30, 2015,

The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Rela ...
Read Project

 19

 FINISHED 

European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI)

Start date: May 1, 2010, End date: Apr 30, 2015,

The aim of EU-GEI is to identify the interactive genetic, clinical and environmental determinants involved in the development, severity and outcome of schizophrenia (EU-GEI, Schiz. Res. 2008; 102: 21-6). In order to identify these interactive determinants, EU-GEI will employ family-based, multidisciplinary research paradigms, which allow for the efficient assessment of gene-environment interaction ...
Read Project

 27

 FINISHED 

A Roadmap for Mental Health Research in Europe (ROAMER)

Start date: Oct 1, 2011, End date: Mar 31, 2015,

"On the regional level, Europe has one of the highest levels of resources for mental health care. Despite this, the high burden and impact of mental disorders in Europe is expected to rise. “ROAdmap for Mental health Research” (ROAMER) is designed to develop a comprehensive, consensus-based roadmap to promote and integrate mental health and well-beingresearch in Europe. Research advances and innov ...
Read Project

 15

 FINISHED 

THERAPEUTIC AND PREVENTIVE IMPACT OF NUTRITIONAL LIPIDS ON NEURONAL AND COGNITIVE PERFORMANCE IN AGING, ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA (LIPIDIDIET)

Start date: Aug 1, 2008, End date: Mar 31, 2015,

Major objective: It is our aim to develop a lipid based diet that is able to delay or prevent onset of Alzheimer’s disease and related diseases and has a stabilizing effect on cognitive performance in aging. Multiple lines of evidence suggest that there is a large overlap between risk factor of these three diseases. Importantly, there is equally strong evidence that prevention and treatment of the ...
Read Project

 19

 FINISHED 

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Start date: Sep 1, 2009, End date: Feb 28, 2015,

Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Read Project

 20

 FINISHED 

Phantom phenomena: A window to the mind and the brain (PHANTOMMIND)

Start date: Jan 1, 2009, End date: Dec 31, 2014,

Phantom experiences occur in almost all amputees but are among the least understood sensory phenomena. Recently changes in the representation of body maps in the brain were found to be related to phantom pain and it has also been demonstrated that there are great similarities between nonpainful phantoms and bodily illusions such as the rubber hand illusion. This research has also shown that the br ...
Read Project

 1

 FINISHED 

Alcohol Measures for Public Health Research Alliance (AMPHORA) (AMPHORA)

Start date: Jan 1, 2009, End date: Dec 31, 2012,

"AMPHORA is a Europe wide project involving researches and research institutions from 14 European countries, and counterparts and organizations from all 27 Member States, that will provide new scientific evidence for the best public health measures to reduce the harm done by alcohol through addressing social and cultural determinants, marketing and advertising, taxes and pricing, availability and ...
Read Project

 33

 FINISHED 

Genomic variations underlying common behavior diseases and cognition trait in human populations (ADAMS)

Start date: Oct 1, 2009, End date: Sep 30, 2012,

"The subject of the proposal is the search and analysis of genomic variations underlying Alzheimer's disease (AD), alcoholism and schizophrenia – wide-spread diseases in human populations. Schizophrenia and alcoholism are common forms of behavior pathology and disability in adult life. AD is a most common form of dementia in human populations. Though the genomic variations presumably associated wi ...
Read Project

 12

 FINISHED 

Serotonin and GABA-B receptors in anxiety : from developmental risk factors to treatment (DEVANX)

Start date: Feb 1, 2008, End date: Jul 31, 2012,

"GABAergic and serotoninergic systems are key players in the control of anxiety states but the precise bases for their action has remained elusive. New findings, brought about by members of this consortium, are radically changing our views on the neurobiological action of these two transmitters and will be the focus of the present proposal. The first original dimension is the discovery of a develo ...
Read Project

 8

 FINISHED 

Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders (SchizDX)

Start date: Oct 1, 2008, End date: Mar 31, 2012,

Schizophrenia and bipolar affective disorder are a major burden to affected individuals and their families and to society at large. These two severe mental illnesses affect at least 2% of the population worldwide, and whilst 50% of sufferers do not receive adequate treatment, they cost hundreds of billions in healthcare provision, treatments and lost earnings. The current diagnosis of schizophreni ...
Read Project

 9